Phase 2
Huntington’s Disease Clinical Trials: Updates on Dalzanemdor and Tominersen
Huntington’s disease, clinical trials, dalzanemdor, tominersen, cognitive impairment, RNA-based therapy, NMDA receptor modulator, Phase 2 and Phase 3 studies
Oculis Announces Phase 2 Results for Licaminlimab in Dry Eye Disease, Despite Limited Statistical Significance
Oculis, Licaminlimab, Dry Eye Disease, Phase 2 Results, Statistical Significance